National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation

Abstract

Background: Cervical cancer is the leading cause of cancer among women in Tanzania, with approximately 10,000 new cases and 7,000 deaths annually. In April 2018, the Government of Tanzania introduced 2 doses of human papillomavirus (HPV) vaccine nationally to adolescent girls to prevent cervical cancer, following a successful 2-year pilot introduction of the vaccine in the Kilimanjaro Region.

Methods: We interviewed key informants at the national level in Tanzania from February to November 2019, using a semi-structured tool to better understand national decision-making and program implementation. We conducted a comprehensive desk review of HPV vaccine introduction materials and reviewed administrative coverage data.

Results: Ten key informants were interviewed from the Ministry of Health, Community Development, Gender, Elderly, and Children, the World Health Organization, and other partners, and HPV vaccine planning documents and administrative coverage data were reviewed during the desk review. Tanzania introduced HPV vaccine to a single-age cohort of 14-year-old girls, with the decision-making process involving the Tanzania Immunization Technical Advisory Group and the national Interagency Coordination Committee. HPV vaccine was integrated into the routine immunization delivery strategy, available at health facilities and through outreach services at community sites, community mobile sites (>10 km from the health facility), and primary and secondary schools. Pre-introduction activities included trainings and microplanning workshops for health workers and school personnel at the national, regional, council, and health facility levels. Over 6,000 health workers and 22,000 school personnel were trained nationwide. Stakeholder and primary health care committee meetings were also conducted at the national level and in each of the regions as part of the advocacy and communication strategy. Administrative coverage of the first dose of HPV vaccine at the end of 2019 was 78%, and second dose coverage was 49%. No adverse events following HPV vaccination were reported to the national level.

Discussion: Tanzania successfully introduced HPV vaccine nationally targeting 14-year-old girls, using routine delivery strategies. Continued monitoring of vaccination coverage will be important to ensure full 2-dose vaccination of eligible girls. Tanzania can consider periodic intensified vaccination and targeted social mobilization efforts, as needed.

Keywords: Human papillomavirus; Human papillomavirus vaccine; Tanzania.

Fig. 1.

Human papillomavirus (HPV) vaccine administrative coverage¹ in the Kilimanjaro Region, Tanzania, 2014–2015 (¹The total number of doses administered to the target population/the total estimated number of people in the target population; administrative coverage provided by the Tanzania Ministry of Health, Community Development, Gender, Elderly, and Children).

Fig. 2.

Tanzania national human papillomavirus (HPV) vaccine introduction decision-making timeline, 2016–2018.

Fig. 3.

Tanzania human papillomavirus (HPV) vaccine administrative coverage¹, April 2018–December 2019 (¹The total number of doses administered to the target population/the total estimated number of people in the target population; administrative coverage provided by the Tanzania Ministry of Health, Community Development, Gender, Elderly, and Children).